5,154 IQVIA Holdings Inc. $IQV Shares Sold by Philadelphia Trust Co.

Philadelphia Trust Co. cut its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 5.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 86,779 shares of the medical research company’s stock after selling 5,154 shares during the quarter. IQVIA comprises 1.5% of Philadelphia Trust Co.’s investment portfolio, making the stock its 19th largest holding. Philadelphia Trust Co. owned approximately 0.05% of IQVIA worth $23,331,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. Compass Financial Management LLC increased its position in IQVIA by 31.9% during the third quarter. Compass Financial Management LLC now owns 157 shares of the medical research company’s stock worth $42,000 after acquiring an additional 38 shares during the period. North Dakota State Investment Board boosted its holdings in IQVIA by 0.8% in the 3rd quarter. North Dakota State Investment Board now owns 5,063 shares of the medical research company’s stock valued at $1,361,000 after purchasing an additional 40 shares during the period. Boston Trust Walden Corp boosted its holdings in IQVIA by 1.9% in the 3rd quarter. Boston Trust Walden Corp now owns 2,650 shares of the medical research company’s stock valued at $712,000 after purchasing an additional 50 shares during the period. Apella Capital LLC grew its position in IQVIA by 4.7% in the 3rd quarter. Apella Capital LLC now owns 1,235 shares of the medical research company’s stock worth $319,000 after purchasing an additional 55 shares during the last quarter. Finally, Brighton Jones LLC grew its position in IQVIA by 0.7% in the 3rd quarter. Brighton Jones LLC now owns 8,151 shares of the medical research company’s stock worth $2,191,000 after purchasing an additional 58 shares during the last quarter. 89.62% of the stock is owned by institutional investors.

Insider Transactions at IQVIA

In other IQVIA news, insider James G. Berkshire sold 2,668 shares of IQVIA stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $261.33, for a total transaction of $697,228.44. Following the completion of the transaction, the insider directly owned 10,890 shares of the company’s stock, valued at approximately $2,845,883.70. This trade represents a 19.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 1.70% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

IQV has been the subject of a number of research analyst reports. Jefferies Financial Group upped their price objective on shares of IQVIA from $220.00 to $290.00 and gave the company a “buy” rating in a research report on Wednesday, July 29th. Mizuho lifted their target price on IQVIA from $275.00 to $300.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 7th. Leerink Partners boosted their price target on IQVIA from $280.00 to $310.00 and gave the company an “outperform” rating in a research note on Thursday, October 8th. Weiss Ratings lowered IQVIA from a “hold (c+)” rating to a “sell (d+)” rating in a research note on Wednesday, October 28th. Finally, William Blair raised IQVIA to a “strong-buy” rating in a report on Tuesday, July 28th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $294.21.

IQVIA Trading Down 1.2%

IQV stock opened at $275.44 on Wednesday. IQVIA Holdings Inc. has a 1-year low of $154.50 and a 1-year high of $284.50. The firm has a market cap of $45.39 billion, a P/E ratio of 33.47, a P/E/G ratio of 2.48 and a beta of 1.16. The business’s 50 day moving average is $267.20 and its 200-day moving average is $211.40. The company has a current ratio of 0.83, a quick ratio of 0.83 and a debt-to-equity ratio of 2.18.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, October 27th. The medical research company reported $3.34 EPS for the quarter, topping the consensus estimate of $3.26 by $0.08. The business had revenue of $4.43 billion during the quarter, compared to the consensus estimate of $4.37 billion. IQVIA had a return on equity of 30.02% and a net margin of 8.05%. IQVIA’s revenue was up 8.0% on a year-over-year basis. During the same quarter last year, the company earned $3.00 EPS. Equities analysts anticipate that IQVIA Holdings Inc. will post 11.53 earnings per share for the current fiscal year.

About IQVIA

IQVIA Holdings Inc. provides clinical research services, healthcare data and analytics, and technology solutions to pharmaceutical, biotechnology, medical-device, and other healthcare organizations. Its services support the development and commercialization of medicines and other healthcare products. The company’s offerings include clinical trial planning and management, real-world data and evidence, consulting, and software and technology platforms for life sciences research and commercial operations.